Cybrexa expands anticancer pipeline

Cybrexa Therapeutics reports it is expanding the application of its proprietary alphalex™ platform to include toxin conjugates and additional next generation synthetic lethality targets.

Two of Cybrexa’s new preclinical pipeline programs include CBX-12 (alphalexTM-exatecan) and CBX-13 (alphalexTM-DM4). Both exatecan and DM4 are highly toxic to cells and require targeted delivery to be used as cancer therapies, making them prime opportunities for the alphalexTM platform.

Both programs are expected to have efficacy across a variety of solid tumors. Preclinical work is ongoing, with publication of initial data expected by mid-2020. more